Evaluating CMR

Metabolic Syndrome and Type 2 Diabetes/CVD Risk



Page: Go to Previous Page 8 of 9 Go to Next Page

Although NCEP-ATP III clinical criteria are the most widely used in studies evaluating metabolic syndrome-related CVD risk, some studies have investigated whether WHO, EGIR, and AACE criteria also indicate increased CVD and type 2 diabetes risk. The most relevant studies are summarized in section Comparison of Screening Tools.

None of the NCEP-ATP III, IDF, WHO, EGIR, and AACE working groups claimed that their criteria were best at defining and classifying individuals with the metabolic syndrome (or insulin resistance syndrome). Each of them called for further research to improve assessment and recommended the use of criteria that take into account obesity, dyslipidemia, insulin resistance, blood pressure, and the pro-inflammatory and pro-thromobotic state. They also agreed that the most promising treatment for the metabolic syndrome is lifestyle therapy because it works on both abdominal obesity and insulin sensitivity.